Table 1.
Multivariable model predicting no primary care, oncology, or surgery visit during a given year from 2–6
| Characteristic | OR (95% CI) | P * |
|---|---|---|
| Age, y | ||
| 18–34 | Referent | <.001 |
| 35–44 | 1.03 (0.42 to 1.65) | |
| 45–54 | 0.96 (0.40 to 1.52) | |
| 55–64 | 0.94 (0.39 to 1.49) | |
| 65–74 | 2.25 (0.91 to 3.60) | |
| ≥75 | 3.44 (1.36 to 5.53) | |
| Race/ethnicity | ||
| White | Referent | <.001 |
| Asian | 1.81 (1.24 to 2.38) | |
| Black | 1.37 (1.14 to 1.60) | |
| Hispanic | 1.14 (0.88 to 1.40) | |
| Other | 1.06 (0.77 to 1.35) | |
| Elixhauser (category) | ||
| None | Referent | .329 |
| 1 | 0.95 (0.81 to 1.09) | |
| 2 | 0.91 (0.76 to 1.06) | |
| 3 | 0.90 (0.72 to 1.08) | |
| ≥4 | 1.09 (0.88 to 1.31) | |
| Radiation | ||
| No | Referent | <.001 |
| Yes | 0.45 (0.38 to 0.52) | |
| Surgery | ||
| Lumpectomy | Referent | .002 |
| Mastectomy | 0.77 (0.64 to 0.90) | |
| Chemotherapy | ||
| No | Referent | <.001 |
| Yes | 0.33 (0.28 to 0.38) | |
| Reconstruction | ||
| No | Referent | .068 |
| Yes | 0.85 (0.70 to 1.00) | |
| Diagnosis year | ||
| 2006 | Referent | <.001 |
| 2007 | 0.99 (0.74 to 1.25) | |
| 2008 | 1.01 (0.76 to 1.27) | |
| 2009 | 1.24 (0.93 to 1.54) | |
| 2010 | 0.94 (0.70 to 1.18) | |
| 2011 | 1.06 (0.80 to 1.32) | |
| 2012 | 1.32 (0.99 to 1.65) | |
| 2013 | 1.29 (0.96 to 1.61) | |
| 2014 | 1.53 (1.12 to 1.95) | |
| Endocrine therapy† | ||
| 0 | Referent | <.001 |
| 1 | 0.20 (0.18 to 0.23) | |
| Year of follow-up | ||
| 2 | Referent | <.001 |
| 3 | 3.33 (2.79 to 3.87) | |
| 4 | 4.61 (3.88 to 5.35) | |
| 5 | 6.06 (5.07 to 7.05) | |
| 6 | 7.98 (6.60 to 9.36) | |
| Prior year visits | ||
| ≥1 visit to primary care, oncology, or surgery | Referent | <.001 |
| No visits | 2.84 (2.29 to 3.38) |
*
Two-sided Wald test. CI = confidence interval; OR = odds ratio.
†
Endocrine therapy defined by at least one pharmacy claim for tamoxifen, letrozole, anastrozole, or exemestane during the year of interest.